Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, hosted a Key Opinion Leader (KOL) call on why exosomes are uniquely suited for vaccine development on March 26, 2020.
Tagged with: Capricor Therapeutics
23 days ago
Navigo Proteins and MDimune Enter into a Research Collaboration on Affilin®-Mediated Targeting of Extracellular Vesicles
May 11, 2021